View ValuationPharmaCorp Rx 将来の成長Future 基準チェック /26 PharmaCorp Rxは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Consumer Retailing 収益成長5.7%収益成長率48.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日03 Jun 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.お知らせ • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252お知らせ • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).お知らせ • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.分析記事 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.お知らせ • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.お知らせ • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.お知らせ • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4お知らせ • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.お知らせ • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.業績と収益の成長予測TSXV:PCRX - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202886N/A77112/31/202796N/A68312/31/202648N/A-2033/31/202624-2-1-1N/A12/31/202521-122N/A9/30/202518022N/A6/30/2025140-20N/A3/31/202510-100N/A12/31/20246-100N/A9/30/20241-2-1-1N/A6/30/20240-1-1-1N/A3/31/2024N/A-1-1-1N/A12/31/2023N/A0-1-1N/A9/30/2023N/A000N/A6/30/2023N/A000N/A3/31/2023N/A-100N/A12/31/2022N/A-100N/A9/30/2022N/A-100N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PCRXの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PCRXの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PCRXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PCRXの収益 ( 48.2% ) Canadian市場 ( 4.6% ) よりも速いペースで成長すると予測されています。高い収益成長: PCRXの収益 ( 48.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PCRXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 11:29終値2026/06/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmaCorp Rx Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Nick CorcoranAcumen Capital Finance Partners LimitedTania Armstrong-WhitworthCanaccord GenuityFred GataliRaymond James Ltd.
Reported Earnings • May 05Full year 2025 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in FY 2024)Full year 2025 results: CA$0.012 loss per share (in line with FY 2024). Revenue: CA$20.9m (up 261% from FY 2024). Net loss: CA$1.48m (loss widened 46% from FY 2024). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 30Third quarter 2025 earnings released: CA$0.004 loss per share (vs CA$0.009 loss in 3Q 2024)Third quarter 2025 results: CA$0.004 loss per share (improved from CA$0.009 loss in 3Q 2024). Revenue: CA$4.80m (up 335% from 3Q 2024). Net loss: CA$427.5k (loss narrowed 56% from 3Q 2024).
お知らせ • Nov 29PharmaCorp Rx Inc. Announces Management ChangesPharma Corp. Rx Inc. announced an executive transition in which Paul Dale has been appointed President and Chief Operating Officer, effective December 1, 2025, as Calvin LeRoux steps aside from the President role and assumes a one-year appointment as Strategic Advisor to the Chief Executive Officer. Mr. Dale has served as PharmaCorp’s Chief Operating Officer since its inception and will now take on broader leadership responsibilities as PharmaCorp advances its national expansion strategy. Mr. LeRoux will conclude his term as President on November 30, 2025. In his new advisory role, he will assist with the transition of responsibilities, contribute to strategic initiatives, and continue providing guidance on matters relating to PharmaChoice Canada. The company also pleased to announce that Sophia Sigler will join the Corporation as Director, Business Development, effective December 1, 2025. Ms. Sigler will lead the PharmaCorp’s business development initiatives, including sourcing acquisition opportunities, managing the transaction pipeline, coordinating due diligence, and supporting pharmacist partners through co-ownership and succession structures.
New Risk • Nov 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$66.8m market cap, or US$47.5m).
Buy Or Sell Opportunity • Nov 21Now 24% overvaluedOver the last 90 days, the stock has fallen 10% to CA$0.43. The fair value is estimated to be CA$0.35, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 156% over the last 3 years. Earnings per share has grown by 43%.
Recent Insider Transactions • Nov 16Executive Chairperson recently bought CA$1.0m worth of stockOn the 12th of November, Alan Simpson bought around 2m shares on-market at roughly CA$0.42 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
お知らせ • Nov 13PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million.PharmaCorp Rx Inc. has completed a Composite Units Offering in the amount of CAD 23.0391 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 47,700,000 Price\Range: CAD 0.42 Discount Per Security: CAD 0.0252
お知らせ • Aug 25PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2025.
Reported Earnings • Aug 18Second quarter 2025 earnings released: CA$0.003 loss per share (vs CA$0.011 loss in 2Q 2024)Second quarter 2025 results: CA$0.003 loss per share (improved from CA$0.011 loss in 2Q 2024). Revenue: CA$4.40m (up CA$4.10m from 2Q 2024). Net loss: CA$384.1k (loss narrowed 36% from 2Q 2024).
お知らせ • Aug 08PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc.PharmaCorp Rx Inc. (TSXV:PCRX) entered into share purchase agreement to acquire Pharmacy business from PharmaChoice Canada Inc. for CAD 2.4 million on June 24, 2025. The purchase price is subject to customary adjustments which will be paid using cash on hand. The Acquisition is expected to close on or about July 31, 2025, subject to satisfaction of customary closing conditions. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business from PharmaChoice Canada Inc on August 7, 2025.
Buy Or Sell Opportunity • Jul 30Now 24% overvaluedOver the last 90 days, the stock has fallen 4.1% to CA$0.47. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
分析記事 • Jul 28Calculating The Fair Value Of PharmaCorp Rx Inc. (CVE:PCRX)Key Insights PharmaCorp Rx's estimated fair value is CA$0.38 based on 2 Stage Free Cash Flow to Equity With CA$0.46...
Buy Or Sell Opportunity • Jul 08Now 29% overvalued after recent price riseOver the last 90 days, the stock has risen 2.1% to CA$0.49. The fair value is estimated to be CA$0.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Jun 04Now 24% overvaluedOver the last 90 days, the stock has fallen 9.8% to CA$0.46. The fair value is estimated to be CA$0.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
New Risk • Feb 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (478% increase in shares outstanding). Revenue is less than US$1m (CA$1.4m revenue, or US$981k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$64.5m market cap, or US$45.3m).
Board Change • Oct 04High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Ken Brownell was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 03PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire Pharmacy business including land and buildings located in Atlanfic Canada for CAD 15.4 million on September 24, 2024. A cash consideration of CAD 15.18 million will be paid by PharmaCorp Rx Inc. The consideration consists of common equity of PharmaCorp Rx Inc. having a value of CAD 0.2 million to be issued for assets of Pharmacy business including land and buildings located in Atlanfic Canada. As part of consideration, CAD 15.38 million is paid towards assets of Pharmacy business including land and buildings located in Atlanfic Canada. For the period ending April 30, 2024, Pharmacy business including land and buildings located in Atlanfic Canada reported total revenue of CAD 10.36 million, net income of CAD 0.44 million, net assets of CAD 2.21 million and total debt of CAD 1.01 million. The transaction is subject to satisfaction of customary closing conditions, including the conditional acceptance of the TSX Venture Exchange. The expected completion of the transaction is October 1, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of Pharmacy business including land and buildings located in Atlanfic Canada on October 2, 2024.
お知らせ • Sep 05PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transaction is that the Vendors will retain a 10% interest in the Acquired Pharmacy and have agreed to continue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024. PharmaCorp Rx Inc. (TSXV:PCRX) completed the acquisition of 90% stake in Pharmacy Located in Western Canada on September 3, 2024.
お知らせ • Aug 23PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million.PharmaCorp Rx Inc. (TSXV:PCRX) agreed to acquire 90% stake in Pharmacy Located in Western Canada for CAD 2.2 million on August 22, 2024. The consideration will be funded from cash. A key aspect of the transacfion is that the Vendors will retain a 10% interest in the Acquired Pharmacy, and have agreed to confinue working at the Acquired Pharmacy, with one of the Vendors entering into a long-term employment agreement as the managing pharmacist. The transaction is subject to satisfaction of customary closing conditions. The expected completion of the transaction is August 30, 2024.
お知らせ • Aug 22PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024PharmaCorp Rx Inc., Annual General Meeting, Oct 02, 2024.
New Risk • Aug 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 366% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (366% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$43.8m market cap, or US$31.6m).
Board Change • Jul 23High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Glenn Fradette is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 08+ 1 more updateProton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million.Proton Capital Corp. has completed a Follow-on Equity Offering in the amount of CAD 20.797658 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 51,994,146 Price\Range: CAD 0.4
お知らせ • May 29Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy.Proton Capital Corp. (TSXV:PTN.P) agreed to acquire 75%stake in Saskatoon Family Pharmacy on May 27, 2024.
お知らせ • Nov 17Proton Capital Corp., Annual General Meeting, Jan 22, 2024Proton Capital Corp., Annual General Meeting, Jan 22, 2024.